Comparison of Authentic and Suspect Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Comparison of Authentic and Suspect Pharmaceuticals
The authors applied near-infrared (NIR) spectrophotometry to assess whether eight drug products were authentic or counterfeit.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 46-52

Appendix I: Further comments about ρ m and δ a criteria


Figure 10. Photograph of test (left) and reference (right) 100-mg Viagra tablets. The test and reference products were of slightly different visual color, as reflected in the 400–800-nm range in Figure 9.
The most similar test and reference spectra were those of Viagra 50 mg, which showed a difference of about 1%. Over the range 400–2500 nm, ρm = 0.0122 and δa = 1.21. Because of high-profile similarity above and below 800 nm, the exclusion of 400–800-nm data had essentially no effect on ρm or δa for Viagra 50 mg. Because of the high-profile similarity above 800 nm for Viagra 100 mg and the modest difference in visual tablet colors, ρm and δa for Viagra 100 mg were larger when 400–800-nm data were included. Figure 10 shows slight visual-color difference between test and referenceViagra 100 mg. The TLC results showed a single spot from test and reference Viagra products that agreed with the TLC results from the sildenafil citrate API.

Acknowledgments

The authors acknowledge the assistance of Mary Lego, education manager at Foss NIR Systems, in acquiring the spectra on a Foss NIRSystems RCA XDS NIR spectrometer.

James E. Polli* is a professor, and Stephen W. Hoag is an associate professor, both at the University of Maryland School of Pharmacy, 20 Penn St., Baltimore, MD 21201,
. Polli is also a member of Pharmaceutical Technology's editorial advisory board. Sharon Flank is CEO of InfraTrac.

*To whom all correspondence should be addressed.

Submitted: Oct. 1, 2008. Accepted: Dec. 15, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. Federal Food, Drug, and Cosmetic Act, Chapters 1–2, http://www.fda.gov/opacom/laws/fdcact/fdcact1.htm, accessed June 10, 2009.

2. FDA, "Counterfeit Drugs Questions and Answers" (Rockville, MD), http://www.fda.gov/oc/initiatives/counterfeit/qa.html, accessed June 15, 2009.

3. FDA, "New FDA Initiative to Combat Counterfeit Drugs" (Rockville, MD), http://www.fda.gov/oc/initiatives/counterfeit/backgrounder.html, accessed June 15, 2009.

4. World Health Organization and the International Federation of Pharmaceutical Manufacturers and Associations, "Counterfeit Drugs" (WHO, IFPMA, Geneva, 1992).

5. B.H. Murray, "Online Distribution of Counterfeit Pharmaceuticals" white paper, (Cyveillance, Arlington, VA, 2001).

6. F. Dimerik, "Bogus Pills Sold on Net, GAO Finds," Bloomberg News (Bloomberg, New York, June 18, 2004).

7. FDA, "Combating Counterfeit Drugs" (Rockville, MD, 2004), http://www.fda.gov/oc/initiatives/counterfeit/report02_04.html, accessed June 10, 2009.

8. S. Flank, "Anticounterfeiting and NIR: A Hong Kong Diary," Pharm. Mfg. online article (2008), http://www.pharmamanufacturing.com/articles/2008/068.html, accessed June 10, 2009.

9. A.S. Tatavarti et al., "Assessment of NIR Spectroscopy for Nondestructive Analysis of Physical and Chemical Attributes of Sulfamethazine Bolus Dosage Forms," AAPS PharmSciTech 6 (01), E91–E99 (2005).

10. J.E. Polli and A.M. McLean, "Novel Direct Curve Comparison Metrics for Bioequivalence," Pharm. Res. 18 (6), 734–741 (2001).

11. P.R. Seo, V.R. Shah, and J.E. Polli, "Novel Metrics to Compare Dissolution Profiles," Pharm. Dev. Technol. 7 (2), 223–231 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here